Salma Abdel, Evidence-Based Medical Researcher

Healthcare professional with over 13 years of experience in hospital and healthcare administration environments. Skilled in Quality Management System Implementation , ISO 9001 and ISO 45001 compliance, Internal Auditing, Risk assessment, CAPA management, KPI monitoring, Oncology Product analysis and Product Leaflet writing.

Joined: March 1, 2026
Articles: 26

Blog, PARP Inhibitors in BRCA mutations

Molecular Mechanisms of Synthetic Lethality: A Clinical Review of PARP Inhibition in BRCA-Mutated Malignancies

Diagram of synthetic lethality mechanism: PARP inhibition in BRCA-mutant cancer cells leading to apoptosis vs. survival in healthy cells.

Medically Reviewed by: Dr. Salma Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center. Fact-Checked by: Generic Oncology Editorial Team. Synthetic lethality is a genetic phenomenon where the simultaneous loss of function in two separate genes results in cell death, while the…

Salma Abdel, Evidence-Based Medical Researcher
March 28, 2026

Supportive & Palliative Care, Blog

Supportive and Palliative Oncology: Clinical Protocols for Quality of Life

chemotherapy induced nausea and vomitting prevention diagram in Supportive and Palliative Oncology

Protocol Overview Historically, the discipline of clinical oncology maintained a singular, aggressive focus on tumor eradication. The primary metric of success was the reduction of tumor burden, often at the severe expense of the patient’s physical and psychological tolerance. Today,…

Salma Abdel, Evidence-Based Medical Researcher
March 26, 2026

Blog, Generic oncolgoy medicines

Evolving Production Standards and Accessibility in Generic Oncology Therapeutics

We have moved beyond the era where cancer care was defined strictly by high-cost, exclusive branded drugs accessible only to a small percentage of the global population. Today, the focus has shifted toward the democratization of treatment through scientific advancement…

Salma Abdel, Evidence-Based Medical Researcher
March 25, 2026

Generic oncolgoy medicines, Blog

Strategies for Managing and Reducing Cancer Medication Costs: A 2026 Guide

The financial burden of cancer medication costs is often described by the medical community as “Financial Toxicity.” This is not just a term for high bills; it is a clinical reality that affects how well a patient recovers. When the…

Salma Abdel, Evidence-Based Medical Researcher
March 23, 2026

Generic oncolgoy medicines

The Science of Identifying High-Quality Generic Oncology Medicines

High-Quality Generic Oncology Medicines verification infograph

In the year 2026, the global oncology market is saturated with options. While the availability of generic medications has made cancer treatment more affordable, it has also introduced a critical challenge for patients and healthcare providers: how to distinguish a…

Salma Abdel, Evidence-Based Medical Researcher
March 21, 2026

Janus Kinase Inhibitors

JAK Inhibitors | Patient Guide to Clinical Efficacy, Safety, and Treatment Outcomes

Medically Reviewed by: Dr. Salma Elreedy, MD (Clinical Oncology & Internal Medicine) Editorial Board: Generic Oncology Medical Review Board Disclaimer: This educational hub is for informational purposes only and does not constitute medical advice. Always consult your board-certified Rheumatologist, Gastroenterologist,…

Salma Abdel, Evidence-Based Medical Researcher
March 20, 2026

Blog

The Clinical Integration of Generic Oncology Medicines

The Science of Molecular Identity and Bioequivalence of Generic Oncology Medicines

Article Overview The news of a cancer diagnosis is a life-changing event that brings immediate emotional and practical challenges. Beyond the medical complexities of the disease, the cost of treatment often becomes a primary concern for patients and their families.…

Salma Abdel, Evidence-Based Medical Researcher
March 20, 2026

Blog, Generic oncolgoy medicines

How Generic Oncology Medicines Reduce the Financial Burden of Cancer Treatment

How Generic oncology medicines reduce the financial toxicity of cancer care

The diagnosis of cancer brings a sudden and immense weight to any family. While the primary goal is health and recovery, the conversation quickly turns to the high cost of treatment. In the medical world, the financial strain of caring…

Salma Abdel, Evidence-Based Medical Researcher
March 19, 2026

HER2-Negative (HER2-), HR+ Breast Cancer

CDK4/6 Pathway Dysregulation in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Mechanism-of-action-of-CDK4-6-inhibitors-Inhibition-of-G1-S-checkpoint | CDK4/6 Pathway

Protocol Summary Receiving an advanced oncology diagnosis necessitates an immediate transition from generalized anatomical staging to precise molecular and genomic profiling. In contemporary clinical oncology, the standard of care dictates that malignancies are evaluated and treated based on their specific,…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

HR+ Breast Cancer, HER2-Negative (HER2-), PIK3CA, AKT1, or PTEN Alteration

AKT Mutation Alterations in Oncology: Molecular Drivers and Targeted Inhibitor Protocols

Schematic-diagram-of-PI3K-Akt-mTOR-pathway-AKT Mutation

Educational Overview Receiving an advanced cancer diagnosis immediately necessitates a transition from generalized anatomical staging to precise molecular profiling. In modern oncology, the standard of care dictates that malignancies are treated based on their specific genetic drivers. Among the most…